CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	235.18	298.26	389.48	211.89	923.03	1,169
Short-Term Investments	1,620	1,606	1,304	1,603	1,456	521.71
Cash & Short-Term Investments	1,855	1,904	1,694	1,815	2,379	1,690
Cash Growth	-11.99%	12.41%	-6.70%	-23.70%	40.75%	79.10%
Accounts Receivable	-	25	200	-	0.31	0.14
Other Receivables	-	2.1	6.5	11.2	8.4	10.7
Receivables	-	27.1	206.5	11.2	8.71	10.84
Prepaid Expenses	8.83	6.21	7.89	26.01	29.68	15.44
Restricted Cash	3.5	-	-	0.5	-	-
Total Current Assets	1,868	1,937	1,908	1,853	2,418	1,717
Property, Plant & Equipment	269.7	277.55	305.94	320.56	312.04	93.03
Long-Term Investments	-	-	1.97	53.13	-	-
Other Intangible Assets	-	-	0.02	0.07	0.13	0.18
Other Long-Term Assets	28.79	27.35	13.57	16.28	22.2	18.14
Total Assets	2,166	2,242	2,230	2,243	2,752	1,828
Accounts Payable	13.06	14.71	38.15	27.43	14.82	9.09
Accrued Expenses	28.29	39.41	40.67	61.33	77.77	54.32
Current Portion of Leases	17.51	17.29	15.63	15.84	12.16	11.36
Current Income Taxes Payable	1.24	0.45	0.44	0.14	0.72	10.47
Current Unearned Revenue	3.02	3.85	4.11	-	1.01	2.34
Other Current Liabilities	56.33	12.08	9.81	16.38	13.4	6.67
Total Current Liabilities	119.45	87.78	108.79	121.11	119.88	94.26
Long-Term Leases	201.85	206.41	223.01	228.18	212.87	50.07
Long-Term Unearned Revenue	12.32	12.32	14.01	12.32	12.32	11.78
Other Long-Term Liabilities	3.32	3.44	0.96	5.97	7.34	7.63
Total Liabilities	336.94	309.95	346.77	367.58	352.42	163.73
Common Stock	2.72	2.7	2.5	2.44	2.39	2.28
Additional Paid-In Capital	3,324	3,294	2,878	2,735	2,598	2,236
Retained Earnings	-1,502	-1,366	-999.7	-846.09	-195.92	-573.58
Treasury Stock	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06
Comprehensive Income & Other	4.14	1.84	1.91	-15.65	-5.07	-0.08
Total Common Equity	1,829	1,932	1,883	1,875	2,399	1,664
Shareholders' Equity	1,829	1,932	1,883	1,875	2,399	1,664
Total Liabilities & Equity	2,166	2,242	2,230	2,243	2,752	1,828
Total Debt	219.36	223.69	238.63	244.02	225.03	61.43
Net Cash (Debt)	1,636	1,680	1,457	1,624	2,154	1,629
Net Cash Growth	-12.67%	15.31%	-10.30%	-24.59%	32.24%	82.77%
Net Cash Per Share	19.16	19.92	18.39	20.89	26.79	24.70
Filing Date Shares Outstanding	86.36	85.77	80.28	78.65	77.07	75.43
Total Common Shares Outstanding	86.36	85.74	80.04	78.51	76.99	73.91
Working Capital	1,748	1,849	1,799	1,732	2,298	1,622
Book Value Per Share	21.18	22.53	23.52	23.89	31.17	22.52
Tangible Book Value	1,829	1,932	1,883	1,875	2,399	1,664
Tangible Book Value Per Share	21.18	22.53	23.52	23.89	31.16	22.51
Machinery	55.01	54.4	53.26	49.62	36.25	29.5
Construction In Progress	5.54	6.12	8.86	6.16	52.4	8.37
Leasehold Improvements	145.85	145.85	143.26	141.68	86.74	25.47

Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q